Related Experiment Video
Updated: Jun 25, 2026
Translational Orthotopic Models of Glioblastoma Multiforme
Published on: February 17, 2023
Translating biology into clinic: the case of glioblastoma
1Laboratory of Molecular Neuro-Oncology and Department of Neurosurgery, University Hospitals, Basel, Switzerland.
Abstract:
GBM, the most common and malignant primary tumor of the CNS, is characterized by exponential growth and diffuse invasiveness. Although the diverse causative genotypes that give rise to a inhomogeneous histological phenotype are well defined, effective therapy inducing tumor cell apoptosis has not been established so far. Following surgery, billions of invasive tumor cells remain to be targeted by systemic and local therapies. Targeting non-overlapping pathways, rather than a single agent approach, is more likely to be effective. The potential of local drug application has not been exploited yet. Systemically, novel drug combinations have to be developed that not only target key molecules at the signaling crossroads but also exploit energy demand and the epigenetic cancer program of GBM.
Insights
Glioblastoma multiforme (GBM) remains a deadly brain cancer with no effective treatments. New combination therapies targeting multiple pathways, including local drug delivery, are needed to induce GBM cell death.
Area of Science:
- Neuro-oncology
- Cancer biology
- Pharmacology
Background:
- Glioblastoma multiforme (GBM) is the most prevalent and aggressive primary central nervous system (CNS) tumor.
- GBM exhibits rapid growth, diffuse invasiveness, and diverse genetic profiles, complicating treatment.
- Current therapies are insufficient to induce tumor cell apoptosis, leaving billions of invasive cells post-surgery.
Purpose of the Study:
- To explore novel therapeutic strategies for GBM, focusing on combination treatments.
- To investigate the potential of local drug delivery for targeting residual GBM cells.
- To develop systemic therapies that target signaling pathways, energy metabolism, and epigenetic alterations in GBM.
Main Methods:
- Review of current GBM treatment limitations.
- Analysis of GBM's biological characteristics, including growth patterns and invasiveness.
- Exploration of multi-targeted therapeutic approaches.
Main Results:
- No specific results are detailed in the provided abstract.
- The abstract highlights the need for novel therapeutic combinations.
- The potential of local drug application is identified as an underexploited area.
Conclusions:
- Effective GBM therapy requires targeting multiple non-overlapping pathways simultaneously.
- Systemic therapies should address key molecular targets, energy demands, and epigenetic factors.
- Local drug delivery presents a promising, yet largely unexploited, strategy for GBM treatment.